Hospital
Owensboro Health INC
Owensboro Health INC was paid $148.83M by Medicaid between Jan 2018 and Dec 2024, across 597 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoOWENSBORO HEALTH INC
OWENSBORO, KY 42303
OWENSBORO, KY 42303
33aNPI1285613612assigned 01/13/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$148.83M
24GClaims3,299,869
24DCodes billed597
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#3 of 36
Median peer was paid$36.08M
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 426,012 | $18.43M | |
| 2019 | 417,169 | $17.17M | |
| 2020 | 408,091 | $16.83M | |
| 2021 | 540,733 | $24.23M | |
| 2022 | 560,403 | $25.81M | |
| 2023 | 538,127 | $27.08M | |
| 2024incomplete | 409,334 | $19.29M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 70,389 | 53,377 | $17.58M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 48,160 | 31,605 | $13.64M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.5% | 43,475 | 37,797 | $8.14M |
| J9271 | Injection, pembrolizumab, 1 mg | 4.8% | 812 | 541 | $7.14M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.2% | 65,986 | 34,311 | $4.77M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.4% | 7,818 | 6,968 | $3.62M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 36,570 | 27,328 | $2.86M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 17,548 | 13,609 | $2.77M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 46,357 | 38,511 | $2.54M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 36,166 | 18,550 | $2.54M |
| G0378 | Hospital observation service, per hour | 1.6% | 24,238 | 10,059 | $2.40M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 35,999 | 31,407 | $2.19M |
585 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 5,119 | $2.13M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 15,368 | $2.06M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 37,498 | $1.99M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.2% | 4,668 | $1.86M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.2% | 1,199 | $1.76M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 8,408 | $1.70M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 24,717 | $1.44M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,787 | $1.38M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 6,552 | $1.30M |
| 80053 | Comprehensive metabolic panel | <1% | 155,065 | $1.22M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 3,744 | $1.15M |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 2,214 | $1.12M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 13,880 | $1.11M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 7,272 | $1.09M |
| 80050 | General health panel | <1% | 39,700 | $1.05M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 31,044 | $1.03M |
| 58571 | <1% | 742 | $983K | |
| C1776 | Joint device (implantable) | <1% | 336 | $923K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,351 | $917K |
| 71045 | Radiologic examination, chest; single view | <1% | 34,888 | $916K |
| 96376 | <1% | 11,298 | $892K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 145,709 | $871K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,484 | $859K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 11,708 | $804K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 37,225 | $774K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,601 | $742K |
| 93458 | <1% | 876 | $735K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 25,027 | $723K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 10,681 | $704K |
| 87631 | <1% | 5,334 | $692K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12,426 | $689K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 33,013 | $675K |
| 64488 | <1% | 1,741 | $669K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16,226 | $652K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 32,743 | $651K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15,195 | $625K |
| 47562 | <1% | 598 | $603K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 19,651 | $600K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,848 | $591K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,574 | $570K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,360 | $536K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 18,999 | $533K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,531 | $524K |
| 36415 | Collection of venous blood by venipuncture | <1% | 171,707 | $509K |
| 93017 | <1% | 3,060 | $506K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 57,121 | $503K |
| 96367 | <1% | 17,217 | $492K | |
| C1769 | Guide wire | <1% | 3,527 | $485K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 3,780 | $467K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 3,134 | $457K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,842 | $433K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,905 | $429K |
| 76770 | <1% | 2,840 | $419K | |
| 00731 | <1% | 2,414 | $415K | |
| 71250 | <1% | 3,608 | $408K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 40,381 | $396K |
| 94760 | <1% | 30,904 | $392K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 7,521 | $374K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 10,193 | $372K |
| 82607 | <1% | 32,631 | $366K | |
| 88342 | <1% | 7,888 | $355K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,452 | $352K |
| 74018 | <1% | 9,370 | $349K | |
| 83735 | <1% | 58,380 | $347K | |
| 83880 | <1% | 16,001 | $342K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,977 | $339K |
| 93971 | <1% | 2,623 | $334K | |
| 76942 | <1% | 1,986 | $332K | |
| 88341 | <1% | 2,930 | $330K | |
| 76642 | <1% | 2,586 | $324K | |
| 87507 | <1% | 1,418 | $324K | |
| 80061 | Lipid panel | <1% | 34,305 | $318K |
| 0240U | <1% | 3,236 | $310K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 26,151 | $305K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,953 | $302K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 22,216 | $302K |
| 76536 | <1% | 2,318 | $301K | |
| 84484 | <1% | 33,134 | $293K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,654 | $272K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 21,021 | $270K |
| 80081 | <1% | 4,007 | $267K | |
| 70486 | <1% | 1,539 | $265K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 15,424 | $250K |
| 00813 | <1% | 1,510 | $249K | |
| 72131 | <1% | 1,752 | $246K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,135 | $240K |
| 72141 | <1% | 1,622 | $239K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 35,264 | $237K |
| 88307 | <1% | 3,206 | $235K | |
| 95811 | <1% | 395 | $232K | |
| 73630 | <1% | 6,294 | $230K | |
| 88142 | <1% | 14,008 | $226K | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | <1% | 1,721 | $220K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 40,168 | $218K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,414 | $218K |
| 88304 | <1% | 5,866 | $212K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 433 | $204K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,094 | $204K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 30,080 | $201K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,155 | $199K |
| 73030 | <1% | 6,081 | $197K | |
| 83690 | <1% | 36,615 | $195K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 2,558 | $195K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 29,651 | $192K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 551 | $190K |
| J3490 | Unclassified drugs | <1% | 10,510 | $189K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,426 | $187K |
| 82728 | <1% | 19,214 | $181K | |
| 73610 | <1% | 4,940 | $181K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 790 | $178K |
| 73564 | <1% | 5,341 | $176K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 26,279 | $173K |
| 78264 | <1% | 930 | $168K | |
| 76870 | <1% | 1,157 | $168K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,175 | $165K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,018 | $164K |
| 94060 | <1% | 2,452 | $163K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,454 | $162K |
| 73130 | <1% | 4,465 | $161K | |
| 96417 | <1% | 2,033 | $161K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,716 | $159K |
| 97161 | <1% | 5,362 | $152K | |
| 71271 | <1% | 1,266 | $143K | |
| 73110 | <1% | 3,901 | $140K | |
| 93225 | <1% | 1,295 | $135K | |
| 11043 | <1% | 358 | $132K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 724 | $132K |
| 58661 | <1% | 115 | $132K | |
| 77080 | <1% | 2,402 | $130K | |
| J2704 | Injection, propofol, 10 mg | <1% | 23,740 | $128K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 3,740 | $127K |
| 82805 | <1% | 3,616 | $125K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 200 | $124K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,078 | $123K |
| 84439 | <1% | 17,058 | $121K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 4,232 | $120K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 12,278 | $119K |
| 82948 | <1% | 24,437 | $119K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,847 | $118K |
| 72100 | <1% | 3,723 | $118K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,207 | $118K |
| 84703 | <1% | 19,485 | $116K | |
| 87186 | <1% | 14,959 | $115K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 5,091 | $113K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 208 | $112K |
| 93970 | <1% | 611 | $111K | |
| 73502 | <1% | 3,649 | $109K | |
| 97597 | <1% | 1,317 | $109K | |
| 72110 | <1% | 3,285 | $107K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,219 | $104K |
| 73562 | <1% | 3,207 | $104K | |
| 86003 | <1% | 3,616 | $104K | |
| 84403 | <1% | 4,303 | $103K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 19,296 | $101K |
| 00811 | <1% | 580 | $101K | |
| 87077 | <1% | 16,948 | $100K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 557 | $99K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 492 | $99K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 981 | $99K |
| 81001 | <1% | 39,065 | $98K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 24,017 | $96K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,430 | $95K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 308 | $94K |
| 95816 | <1% | 529 | $94K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 24,282 | $92K |
| 12001 | <1% | 1,039 | $92K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,989 | $92K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,313 | $91K |
| 80074 | <1% | 2,330 | $91K | |
| 87807 | <1% | 3,982 | $91K | |
| 87070 | <1% | 14,370 | $90K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14,806 | $90K |
| 78227 | <1% | 408 | $89K | |
| 70496 | <1% | 633 | $89K | |
| 84112 | <1% | 1,306 | $89K | |
| 70498 | <1% | 513 | $88K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,774 | $88K |
| 93975 | <1% | 503 | $88K | |
| 82746 | <1% | 7,818 | $87K | |
| 86235 | <1% | 2,155 | $87K | |
| 82550 | <1% | 16,167 | $87K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 662 | $86K |
| 84425 | <1% | 3,208 | $85K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 117 | $85K |
| 83550 | <1% | 11,452 | $83K | |
| 90715 | <1% | 1,907 | $82K | |
| 74022 | <1% | 2,101 | $80K | |
| 94729 | <1% | 1,797 | $79K | |
| 99152 | <1% | 1,371 | $78K | |
| 87634 | <1% | 3,266 | $77K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 12,862 | $77K |
| 85610 | <1% | 25,067 | $76K | |
| 73590 | <1% | 2,133 | $75K | |
| 83516 | <1% | 6,376 | $70K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 6,485 | $70K |
| 86803 | <1% | 6,123 | $68K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,892 | $68K |
| 10060 | <1% | 777 | $68K | |
| 82150 | <1% | 13,452 | $67K | |
| 87529 | <1% | 2,313 | $65K | |
| 83970 | <1% | 4,369 | $65K | |
| 72040 | <1% | 2,024 | $64K | |
| 83540 | <1% | 12,820 | $64K | |
| 83605 | <1% | 6,937 | $64K | |
| 81025 | <1% | 10,760 | $63K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 10,760 | $61K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,564 | $61K |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 270 | $60K |
| 77336 | <1% | 490 | $60K | |
| 87040 | <1% | 7,109 | $59K | |
| 0001A | <1% | 4,928 | $59K | |
| 84145 | <1% | 2,837 | $58K | |
| 73090 | <1% | 1,510 | $58K | |
| 72050 | <1% | 1,787 | $57K | |
| 70491 | <1% | 316 | $57K | |
| 86140 | <1% | 13,276 | $57K | |
| 84702 | <1% | 4,595 | $57K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 12,181 | $55K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,897 | $54K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,964 | $54K |
| 77065 | Tomosynthesis, mammo | <1% | 1,600 | $54K |
| 97116 | <1% | 3,402 | $54K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 241 | $53K |
| 97162 | <1% | 3,027 | $53K | |
| 84146 | <1% | 2,674 | $53K | |
| 85379 | <1% | 6,635 | $53K | |
| 93798 | <1% | 1,507 | $52K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 59 | $52K |
| 86850 | <1% | 7,628 | $51K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 8,328 | $49K |
| 93270 | <1% | 373 | $49K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,139 | $48K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,829 | $47K |
| 81003 | <1% | 24,896 | $47K | |
| 73221 | <1% | 317 | $47K | |
| 12011 | <1% | 466 | $46K | |
| 76000 | <1% | 401 | $46K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 565 | $46K |
| 0002A | <1% | 3,259 | $45K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,304 | $44K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,420 | $44K |
| 82043 | <1% | 7,693 | $43K | |
| 49083 | <1% | 206 | $41K | |
| 85730 | <1% | 7,266 | $41K | |
| 75574 | <1% | 233 | $40K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,125 | $39K |
| 80076 | <1% | 5,043 | $39K | |
| 84270 | <1% | 2,340 | $39K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,076 | $38K |
| 83001 | <1% | 2,184 | $38K | |
| 72072 | <1% | 1,140 | $38K | |
| 73080 | <1% | 1,094 | $38K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,132 | $37K |
| 29581 | <1% | 379 | $36K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 723 | $36K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 36 | $35K |
| 76882 | <1% | 292 | $35K | |
| 94727 | <1% | 1,161 | $35K | |
| 59025 | Fetal non-stress test | <1% | 572 | $34K |
| 86703 | <1% | 2,819 | $34K | |
| 84481 | <1% | 2,524 | $33K | |
| 64415 | <1% | 334 | $32K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 17,642 | $32K |
| 73700 | <1% | 260 | $32K | |
| 86039 | <1% | 3,596 | $31K | |
| 73140 | <1% | 834 | $31K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,864 | $31K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,434 | $31K |
| 82378 | <1% | 2,018 | $31K | |
| 52332 | <1% | 25 | $29K | |
| 83002 | <1% | 1,627 | $29K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 3,663 | $29K |
| 87081 | <1% | 5,252 | $29K | |
| 87205 | <1% | 8,473 | $29K | |
| 85027 | <1% | 6,267 | $28K | |
| 86480 | <1% | 681 | $28K | |
| 43235 | <1% | 77 | $28K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 485 | $28K |
| 82670 | <1% | 1,147 | $27K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 243 | $27K |
| 86787 | <1% | 1,093 | $27K | |
| 99218 | <1% | 736 | $27K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 3,193 | $26K |
| 73070 | <1% | 699 | $26K | |
| 85652 | <1% | 11,732 | $26K | |
| 87210 | <1% | 5,376 | $26K | |
| 86665 | <1% | 1,515 | $26K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 441 | $25K |
| 95819 | <1% | 153 | $25K | |
| 86769 | <1% | 991 | $25K | |
| 80299 | <1% | 1,617 | $25K | |
| 84681 | <1% | 1,200 | $25K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 126 | $25K |
| 73560 | <1% | 771 | $24K | |
| 82570 | <1% | 5,702 | $24K | |
| 87184 | <1% | 3,630 | $24K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,521 | $23K |
| 96415 | <1% | 341 | $23K | |
| 86376 | <1% | 1,674 | $23K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,504 | $23K |
| 82565 | <1% | 3,394 | $23K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,185 | $22K |
| 82784 | <1% | 4,258 | $22K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,065 | $22K |
| 99153 | Mod sedat endo service >5yrs | <1% | 276 | $21K |
| 86901 | <1% | 6,457 | $20K | |
| 87449 | <1% | 1,813 | $20K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 428 | $20K |
| 83525 | <1% | 1,410 | $19K | |
| 86300 | <1% | 1,360 | $19K | |
| 44970 | <1% | 12 | $19K | |
| 76801 | <1% | 88 | $19K | |
| 88302 | <1% | 613 | $19K | |
| 80164 | <1% | 1,422 | $19K | |
| 86900 | <1% | 6,586 | $19K | |
| 82533 | <1% | 1,333 | $18K | |
| 87486 | <1% | 574 | $18K | |
| 96411 | <1% | 210 | $17K | |
| 77066 | Tomosynthesis, mammo | <1% | 427 | $17K |
| 71101 | <1% | 548 | $17K | |
| 87340 | <1% | 988 | $17K | |
| 87581 | <1% | 551 | $17K | |
| 72170 | <1% | 525 | $16K | |
| 83883 | <1% | 1,418 | $16K | |
| 93880 | <1% | 137 | $16K | |
| 80069 | <1% | 3,841 | $16K | |
| 97014 | <1% | 620 | $16K | |
| 74246 | <1% | 231 | $16K | |
| 87902 | <1% | 84 | $16K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 946 | $16K |
| 94726 | <1% | 349 | $15K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,644 | $15K |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 402 | $15K |
| 92650 | <1% | 658 | $15K | |
| C1729 | Catheter, drainage | <1% | 162 | $15K |
| 82248 | <1% | 3,687 | $15K | |
| 82247 | <1% | 2,989 | $15K | |
| 84156 | <1% | 4,460 | $15K | |
| 86592 | <1% | 3,461 | $15K | |
| 86677 | <1% | 1,197 | $14K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 416 | $14K |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 130 | $14K |
| 97166 | <1% | 623 | $14K | |
| 97802 | <1% | 806 | $14K | |
| 73552 | <1% | 419 | $14K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,095 | $14K |
| 64721 | <1% | 27 | $13K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,954 | $13K |
| 82785 | <1% | 1,082 | $13K | |
| 86708 | <1% | 931 | $12K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 83 | $12K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,560 | $12K |
| 86008 | <1% | 1,011 | $12K | |
| 87324 | <1% | 1,459 | $12K | |
| 86664 | <1% | 723 | $12K | |
| 72020 | <1% | 450 | $12K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 169 | $11K |
| 83615 | <1% | 2,241 | $11K | |
| 82575 | <1% | 1,293 | $11K | |
| 82977 | <1% | 1,427 | $11K | |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | <1% | 421 | $11K |
| 84550 | <1% | 3,074 | $11K | |
| 84153 | <1% | 946 | $11K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 738 | $11K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 168 | $11K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 15 | $11K |
| 84100 | <1% | 2,921 | $10K | |
| 72128 | <1% | 63 | $10K | |
| 84144 | <1% | 392 | $10K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,520 | $10K |
| 86923 | <1% | 831 | $10K | |
| 12002 | <1% | 109 | $10K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,947 | $10K |
| 86757 | <1% | 494 | $10K | |
| 77300 | <1% | 33 | $10K | |
| 93242 | <1% | 872 | $9K | |
| 73060 | <1% | 261 | $9K | |
| 86334 | <1% | 350 | $9K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 836 | $9K |
| 83655 | <1% | 846 | $9K | |
| 0003A | <1% | 707 | $9K | |
| 87625 | <1% | 375 | $8K | |
| 83013 | <1% | 157 | $8K | |
| 82140 | <1% | 708 | $8K | |
| 72070 | <1% | 235 | $8K | |
| 84165 | <1% | 869 | $8K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 70 | $7K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 162 | $7K |
| 83721 | <1% | 1,256 | $7K | |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 313 | $7K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,146 | $7K |
| 86696 | <1% | 475 | $7K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 1,637 | $7K |
| 80047 | <1% | 399 | $7K | |
| 82553 | <1% | 788 | $7K | |
| 93922 | <1% | 82 | $7K | |
| 72081 | <1% | 173 | $7K | |
| C1724 | Catheter, transluminal atherectomy, rotational | <1% | 17 | $7K |
| 84436 | <1% | 1,280 | $7K | |
| 86663 | <1% | 636 | $7K | |
| 98960 | <1% | 226 | $7K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 728 | $7K |
| 84132 | <1% | 1,590 | $6K | |
| C1758 | Catheter, ureteral | <1% | 146 | $6K |
| 86430 | <1% | 1,316 | $6K | |
| 82731 | <1% | 105 | $6K | |
| 84630 | <1% | 370 | $6K | |
| 90686 | <1% | 256 | $6K | |
| 93351 | <1% | 22 | $6K | |
| 74420 | <1% | 47 | $6K | |
| 95812 | <1% | 32 | $6K | |
| 82270 | <1% | 2,150 | $6K | |
| 83630 | <1% | 474 | $6K | |
| 82105 | <1% | 329 | $6K | |
| 88300 | <1% | 341 | $6K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,307 | $6K |
| 88738 | <1% | 587 | $6K | |
| 88312 | <1% | 182 | $6K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 204 | $6K |
| 86618 | <1% | 375 | $5K | |
| 86308 | <1% | 1,347 | $5K | |
| 43259 | <1% | 30 | $5K | |
| 0097U | <1% | 15 | $5K | |
| 81511 | <1% | 75 | $5K | |
| 36430 | <1% | 63 | $5K | |
| 36592 | <1% | 288 | $5K | |
| 86200 | <1% | 451 | $5K | |
| 82627 | <1% | 271 | $5K | |
| 83520 | <1% | 474 | $5K | |
| 74178 | <1% | 33 | $5K | |
| 86431 | <1% | 820 | $5K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 28 | $5K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 28 | $5K |
| 87045 | <1% | 289 | $5K | |
| 0011A | <1% | 690 | $5K | |
| 74221 | <1% | 100 | $5K | |
| 88365 | <1% | 126 | $5K | |
| 86695 | <1% | 443 | $5K | |
| 82950 | <1% | 1,369 | $5K | |
| 86706 | <1% | 379 | $5K | |
| 97803 | <1% | 384 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 827 | $4K |
| 84480 | <1% | 377 | $4K | |
| 84446 | <1% | 298 | $4K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 29 | $4K |
| 84590 | <1% | 213 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 366 | $4K |
| 0004A | <1% | 305 | $4K | |
| 83498 | <1% | 112 | $4K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 593 | $4K |
| 82024 | <1% | 135 | $3K | |
| 76937 | <1% | 15 | $3K | |
| G0424 | Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day | <1% | 119 | $3K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 17 | $3K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 34 | $3K |
| 74230 | <1% | 50 | $3K | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 595 | $3K |
| 93016 | <1% | 189 | $3K | |
| 87177 | <1% | 184 | $3K | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 302 | $3K |
| 84402 | <1% | 118 | $3K | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 431 | $3K |
| 97165 | <1% | 218 | $3K | |
| 84460 | <1% | 857 | $3K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 953 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 177 | $3K |
| 95813 | <1% | 16 | $3K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 44 | $3K |
| 92611 | <1% | 40 | $3K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 51 | $3K |
| 29125 | <1% | 72 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 333 | $3K |
| 0012A | <1% | 367 | $3K | |
| 74183 | <1% | 28 | $3K | |
| 64447 | <1% | 28 | $2K | |
| 84520 | <1% | 704 | $2K | |
| 87046 | <1% | 275 | $2K | |
| 84450 | <1% | 763 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 35 | $2K |
| 82010 | <1% | 388 | $2K | |
| 88360 | <1% | 42 | $2K | |
| 86800 | <1% | 165 | $2K | |
| 82947 | <1% | 1,091 | $2K | |
| 93923 | <1% | 14 | $2K | |
| 82365 | <1% | 133 | $2K | |
| 0071A | <1% | 136 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,342 | $2K |
| 01922 | <1% | 13 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 114 | $2K |
| 77075 | <1% | 16 | $2K | |
| 91200 | <1% | 29 | $2K | |
| 85018 | <1% | 908 | $2K | |
| 64450 | <1% | 13 | $2K | |
| 70360 | <1% | 42 | $2K | |
| 0124A | <1% | 180 | $2K | |
| 86225 | <1% | 96 | $2K | |
| 92582 | <1% | 49 | $2K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 121 | $2K |
| 92586 | <1% | 65 | $2K | |
| 86704 | <1% | 151 | $2K | |
| 83010 | <1% | 69 | $2K | |
| 92557 | <1% | 56 | $2K | |
| 0013A | <1% | 110 | $1K | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 952 | $1K |
| 86255 | <1% | 72 | $1K | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 51 | $1K |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 77 | $1K |
| 77061 | <1% | 146 | $1K | |
| 88112 | <1% | 34 | $1K | |
| 85014 | <1% | 758 | $1K | |
| 80177 | <1% | 131 | $1K | |
| 83921 | <1% | 69 | $1K | |
| 82310 | <1% | 56 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 15 | $1K |
| 86160 | <1% | 109 | $1K | |
| 87521 | Neg quan hep c or qual rna | <1% | 30 | $1K |
| 3044F | <1% | 9,573 | $1K | |
| 80178 | <1% | 103 | $1K | |
| 0072A | <1% | 78 | $1K | |
| 82172 | <1% | 32 | $1K | |
| 83993 | <1% | 63 | $1K | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 232 | $935.49 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 16 | $930.09 |
| 83090 | <1% | 36 | $866.12 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 204 | $854.36 |
| 97164 | <1% | 60 | $834.60 | |
| 0054A | <1% | 84 | $820.98 | |
| 73522 | <1% | 30 | $809.73 | |
| 96368 | <1% | 34 | $757.35 | |
| 82239 | <1% | 32 | $724.93 | |
| A9270 | Non-covered item or service | <1% | 4,296 | $709.41 |
| 82103 | <1% | 61 | $699.66 | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 88 | $687.85 |
| 29515 | <1% | 18 | $683.30 | |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | <1% | 142 | $680.45 |
| 97168 | <1% | 28 | $662.62 | |
| 81050 | <1% | 261 | $659.82 | |
| 88173 | <1% | 15 | $651.52 | |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | <1% | 35 | $642.13 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 14 | $640.42 |
| 89051 | <1% | 154 | $630.75 | |
| 83789 | <1% | 16 | $599.15 | |
| 90714 | <1% | 12 | $597.51 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 184 | $584.06 |
| 73100 | <1% | 16 | $565.94 | |
| 0064A | <1% | 46 | $552.62 | |
| 87641 | <1% | 14 | $543.85 | |
| 84305 | <1% | 12 | $541.22 | |
| 88364 | <1% | 19 | $505.32 | |
| 86304 | <1% | 14 | $449.70 | |
| 73660 | <1% | 13 | $448.32 | |
| 73000 | <1% | 12 | $430.08 | |
| 81005 | <1% | 159 | $414.37 | |
| 81002 | <1% | 159 | $390.23 | |
| 84207 | <1% | 16 | $376.50 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 46 | $372.63 |
| 0031A | <1% | 26 | $361.71 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 19 | $339.02 |
| 85347 | <1% | 22 | $335.55 | |
| 77062 | <1% | 29 | $329.61 | |
| 84134 | <1% | 17 | $321.53 | |
| 0052A | <1% | 16 | $318.98 | |
| 84155 | <1% | 146 | $313.88 | |
| 84160 | <1% | 31 | $287.54 | |
| 82525 | <1% | 22 | $273.07 | |
| 88311 | <1% | 20 | $262.69 | |
| 51798 | <1% | 12 | $254.78 | |
| 36600 | <1% | 16 | $250.62 | |
| 86674 | <1% | 13 | $216.05 | |
| 85660 | <1% | 39 | $196.43 | |
| 86705 | <1% | 14 | $177.37 | |
| 85045 | <1% | 59 | $174.03 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 27 | $151.14 |
| 84157 | <1% | 42 | $134.96 | |
| 91320 | <1% | 21 | $110.88 | |
| 84300 | <1% | 13 | $104.45 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 58 | $96.71 |
| G2063 | Qualified nonphysician healthcare professional online assessment and management service, for an established patient, for up to seven days, cumulative time during the 7 days; 21 or more minutes | <1% | 24 | $95.82 |
| 85049 | <1% | 16 | $95.21 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 27 | $65.88 |
| 3045F | <1% | 1,207 | $52.05 | |
| 99499 | <1% | 67 | $39.10 | |
| 3046F | <1% | 1,294 | $17.46 | |
| 3051F | <1% | 545 | $0.02 | |
| 3052F | 0% | 302 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRANALLO, RUSS (VICE PRESIDENT OF FINANCIAL SERVICE)
| Provider | Location | Paid |
|---|---|---|
| Owensboro Health Twin Lakes Regional Medical Center, INC | Leitchfield, KY | $17.02M |
| Owensboro Health INC | Owensboro, KY | $2.19M |
| Owensboro Health Medical Group INC | Owensboro, KY | $9K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.